Literature DB >> 9826127

Cellular localization of kallistatin and tissue kallikrein in human pancreas and salivary glands.

W C Wolf1, R A Harley, D Sluce, L Chao, J Chao.   

Abstract

The tissue kallikrein-kinin system contributes to the regulation of local blood flow, vascular permeability, inflammatory responses, and ion transport. Tissue kallikrein is a serine proteinase which produces vasoactive kinin peptides. Kallistatin specifically binds to tissue kallikrein and inhibits its proteolytic activity. To investigate their anatomical relationship in the human pancreas and salivary glands, the expression and localization of kallistatin and tissue kallikrein were identified by immunoassays, immunohistochemistry, and in situ hybridization histochemistry. Human kallistatin and tissue kallikrein levels were measured by ELISA and radioimmunoassay, respectively, in pancreatic and salivary tissue extracts, and in pancreatic fluid and saliva. Immunoreactive kallistatin and kallikrein were colocalized in acinar cells of the human pancreas by immunohistochemistry. In situ hybridization histochemistry confirmed the presence of both mRNAs in pancreatic acini. In salivary glands, kallistatin and kallikrein mRNAs were also colocalized in serous acinar cells, and the kallikrein transcript was further localized to striated and interlobular ducts. Immunoreactive kallistatin was localized in serous acinar and demilune cells of salivary glands and kallikrein was localized to the epithelium of striated and interlobular ducts. The colocalization and/or coexpression of human tissue kallikrein and kallistatin in the pancreas and salivary glands suggest a role for kallistatin in the regulation of tissue kallikrein in these organs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826127     DOI: 10.1007/s004180050309

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  7 in total

1.  A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.

Authors:  W C Wolf; D M Evans; L Chao; J Chao
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation.

Authors:  Hang Yin; Lin Gao; Bo Shen; Lee Chao; Julie Chao
Journal:  Hypertension       Date:  2010-06-21       Impact factor: 10.190

3.  Detection of tissue kallikrein and kinin B1 and B2 receptor mRNAs in human brain by in situ RT-PCR.

Authors:  R Mahabeer; S Naidoo; D M Raidoo
Journal:  Metab Brain Dis       Date:  2000-12       Impact factor: 3.584

4.  Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.

Authors:  Antoni Stadnicki; Urszula Mazurek; Maciej Gonciarz; Danuta Plewka; Grazyna Nowaczyk; Joanna Orchel; Ezbieta Pastucha; Andrzej Plewka; Tadcusz Wilczok; Robert W Colman
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

5.  Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents.

Authors:  Haidong Zhu; Julie Chao; Ishita Kotak; Dehuang Guo; Samip J Parikh; Jigar Bhagatwala; Yutong Dong; Sagar Y Patel; Chris Houk; Lee Chao; Yanbin Dong
Journal:  Metabolism       Date:  2012-11-26       Impact factor: 8.694

6.  Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis.

Authors:  Zhiyun Cheng; Yinghui Lv; Suqiu Pang; Ruyu Bai; Mingxi Wang; Shuyu Lin; Tianwen Xu; Duncan Spalding; Nagy Habib; Ruian Xu
Journal:  Acta Pharm Sin B       Date:  2015-04-07       Impact factor: 11.413

7.  Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms.

Authors:  Misol Do; Dohyun Han; Joseph Injae Wang; Hyunsoo Kim; Wooil Kwon; Youngmin Han; Jin-Young Jang; Youngsoo Kim
Journal:  Clin Proteomics       Date:  2018-04-18       Impact factor: 3.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.